4CPS-125 Preexposure prophylaxis in men at high risk for HIV-1 infection

• Published in: European journal of hospital pharmacy. Science and practice 2023-03, Vol.30 (Suppl 1), p.A64-A64
• Main Authors: Barreiro Fernandez, EM, Dominguez Santana, CM, Rios Sanchez, E, Blanco Castaño, MA, Salmeron Navas, FJ
• Format: Article
• Language: English
• Subjects: Conflicts of interest; Disease prevention; HIV; Human immunodeficiency virus; Infections; Section 4: Clinical pharmacy services; Sexually transmitted diseases; STD
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2023-eahp.135

Background and ImportanceThe Preexposure Prophylaxis (PrEP) for HIV infection with the drugs tenofovir and emtricitabine (FTC/TDF) is recommended by World Health Organization as part of HIV prevention to people at substantial risk HIV infection. Many countries have included it in their healthy police. However, there is a lack of information on its implementation in real practice.Aim and ObjectivesTo evaluate adherence, the effectiveness and safety to treatment for PrEP.Material and MethodsA retrospective and descriptive study of all adult patients who used FTC/TDF for PrEP from September 2020 to September 2022. Clinical data were obtained from digital clinical history and the prescription software Dominion®: sex, age, duration of treatment, high-risk for HIV and adherence to treatment.The adherence to treatment was measured using the dispensing registry. Effectiveness was determined by relative reduction of HIV incidence; HIV testing was performed every three months during this study. In terms of safety, adverse events (AE) were recorded.ResultsForty patients, 100% men, were included, with an average aged of 35 (20-57) years. All patients were received (FTC/TDF), once daily. The average duration of treatment was 6 months (1-30), 8 patients received only two months. All patients were at high risk for HIV, defined as: sexual risk behaviour (ten or more sexual partners and any bacterial sexually transmitted infections (STIs) last year). 25% patients had discontinued therapy due to lack of adherence.None of these patients were diagnosed HIV during study. 100% relative reduction of HIV incidence.No treatment-associated adverse effects were observed, although 75% of patients had PrPE-associated bacterial STIs.Conclusion and RelevanceA quarter of patients were non-adherent to treatment, a possible alternative would be on-demand regimen in these cases.In terms of efficacy, a greater therapeutic result was observed, becoming a good tool prevention.PrEP used was associated high increased bacterial STIs, probably due to not using a condom.References and/or AcknowledgementsConflict of InterestNo conflict of interest